M
Mesoblast Limited
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Mesoblast Limited
Revenue$7.5M▼ 76.8% YoYFY 2021
Operating income—
Net profit−$98.8M▼ 26.8% YoY
Shareholders' equity—
Market cap$1.6BMESO · $12.39
Competitors10identified
About Mesoblast Limited
Sectors
Company details
- Founded
- 2015
- Listed
- Nasdaq: MESO (since 2015)
Operational Areas of Mesoblast Limited
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameMesoblast Limited
TickerMESO
ExchangeNasdaq
CountryAustralia
SEC CIK0001345099
Listed since2015
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
MESO · Nasdaq · SEC CIK 0001345099
Last price · 28 Oct 2026
$12.39
+0.90%
Market cap$1.6B
P/E—On FY 2021 diluted EPS
Volume107,364
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOAustraliaListed 2015
MESO share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Mesoblast Limited
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.